Vivosim Labs (VIVS)Chief Commercial Officer bought ~$2.8K

~$2.8K

Approx. value · 10K sh @ $0.2804

10K

Holds after · shares reported

Traded

Aug 31, 2026

Filed

Sep 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 16, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Jul 20, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On July 20, 2026, VivoSim Labs, Inc., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company’s Annual Report on Form 10-K for the period ended March 31, 2026, reported stockholders’ equity of $(1,099,000), and as of July 20, 2026, the Company did not meet the…”
3. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
4. Aug 17, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On August 17, 2026, VivoSim Labs, Inc., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer met the requirement to maintain a minimum bid price of $1…”
5. Aug 31, 2026 · this disclosureInsider · First insider buy since Aug 2021Officer purchased ~$2.8K of VIVS shares in the open market

What came next

1. Sep 30, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On September 30, 2026, VivoSim Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the amendment and restatement of the VivoSim Labs, Inc. Amended and Restated 2022 Equity Incentive Plan (the “Amended and Restated Plan”) to increase the number of shares reserved for issuance thereunder by 3,165,000 shares.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vivosim Labs

For Vivosim Labs, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VIVS page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Vivosim Labs

• SEC Form 4Nov 20, 2025

Everything OQRO holds on this company is on its VIVS page.